AstraZeneca acquires vaccine biotech Omniose to bolster pipelineAstraZeneca acquired early-stage US biotech Omniose, which is developing vaccines against serious bacterial infections, integrating it into its infectious diseases division.Nov 10, 2026·2 sourcesMergers & acquisitions (M&A)Antimicrobial resistanceMergers and acquisitionsInfectious diseaseBiotech innovationVaccine developmentPharmaceutical IndustryBiotechnologyCorporate strategy00
